Market Overview

UPDATE: Morgan Stanley Downgrades Catamaran on Balanced Risk-Reward

Benzinga's Top Downgrades
UBS Downgrades Catamaran To Neutral
CVS Health's PBM Business Could Be Under Threat (Seeking Alpha)

In a report published Monday, Morgan Stanley analyst Ricky R. Goldwasser downgraded the rating on Catamaran Corp. (NASDAQ: CTRX) from Overweight to Equal-Weight, and removed the $60.00 price target.

In the report, Morgan Stanley noted, “A maturing growth profile and premium to the group likely cap CTRX's multiple expansion opportunity. While we think mgmt will execute and grow EPS via M&A and CI, with topline CAGR moderating to 25% thru ‘15 vs. 75% from '08-‘13E and given evolving PBM dynamics, we view risk-reward as balanced.”

Catamaran Corp. closed on Friday at $49.52.

Latest Ratings for CTRX

Jun 2015UBSDowngradesBuyNeutral
Apr 2015Maxim GroupDowngradesBuyHold
Apr 2015Argus ResearchDowngradesBuyHold

View More Analyst Ratings for CTRX
View the Latest Analyst Ratings

Posted-In: Morgan Stanley Ricky R. GoldwasserAnalyst Color Downgrades Analyst Ratings


Related Articles (CTRX)

Get Benzinga's Newsletters